An intervention for treating alcohol dependence: relating elements of Medical Management to patient outcomes with implications for primary care.
(73/186)
(+info)
Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
(74/186)
(+info)
Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
(75/186)
(+info)
Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin.
(76/186)
(+info)
Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
(77/186)
OBJECTIVE: The purpose of this study was to examine the nature of the effect of placebo medication plus accompanying medical management in the treatment of alcohol dependence. METHOD: The National Institute on Alcohol Abuse and Alcoholism COMBINE (Combining Medications and Behavioral Interventions) study, a randomized controlled double-blind trial of 1,383 alcohol-dependent patients, compared combinations of medications (acamprosate [Campral] and naltrexone [ReVia]) and behavioral therapy (medical management and specialist-delivered behavioral therapy) for alcohol dependence. This report focuses on a subset of that study population (n = 466) receiving (1) specialized behavioral therapy alone (without pills), (2) specialized behavioral therapy + placebo medication + medical management, or (3) placebo + medical management. RESULTS: During 16 weeks of treatment, participants receiving behavioral therapy alone had a lower percentage of days abstinent (66.6%) than did the participants receiving placebo and medical management (73.1%) or those receiving specialized behavioral therapy + placebo + medical management (79.4%). The group receiving behavioral therapy alone relapsed to heavy drinking more often (79.0%) than those receiving behavioral therapy + placebo + medical management (71.2%). This report focuses on potential explanations for this finding. The two groups of participants receiving placebo + medical management were more likely to attend Alcoholics Anonymous meetings during treatment (32.7% and 32.0% vs 20.4%) and were less likely to withdraw from treatment (14.1% and 22.9% vs 29.3%). CONCLUSIONS: There appeared to be a significant "placebo effect" in the COMBINE Study, consisting of pill taking and seeing a health care professional. Contributing factors to the placebo response may have included pill taking itself, the benefits of meeting with a medical professional, repeated advice to attend Alcoholics Anonymous, and optimism about a medication effect. (+info)
Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
(78/186)
(+info)
Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor.
(79/186)
(+info)
Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence.
(80/186)
(+info)